Takeda Pharmaceutical Company Limited (VIE:TKD)

Market Cap	47.11B +16.2%
Revenue (ttm)	24.25B -2.5%
Net Income	613.43M -45.7%
EPS	0.38 -45.9%
Shares Out	n/a
PE Ratio	76.79
Forward PE	n/a
Dividend	1.17 (4.09%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	n/a
Open	29.48
Previous Close	29.42
Day's Range	29.48 - 29.53
52-Week Range	22.83 - 29.66
Beta	n/a
RSI	75.34
Earnings Date	Jan 29, 2026

About VIE:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In fiscal year 2025, VIE:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY